For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C gr...
“Stopping tyrosine kinase inhibitor therapy is something we get a lot of questions about from both patients and their referring physicians,” said Amelia A. Langston, MD. Although their efficacy is ind...
For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C gr...
“Stopping tyrosine kinase inhibitor therapy is something we get a lot of questions about from both patients and their referring physicians,” said Amelia A. Langston, MD. Although their efficacy is ind...
At the 2024 Debates and Didactics in Hematology and Oncology Conference, sponsored by Emory’s Winship Cancer Institute, cardiologist-by-training Anant Mandawat, MD, FACC, briefly reviewed how the emer...
